This poster describes some of the microbiome analyses results obtained on a in vivo murine model of food allergy...
Microbiome
![[POSTER] Fecal microbiota profile at diagnosis in the French IMODI cohort of breast cancer](https://www.biofortis.fr/wp-content/uploads/2019/12/ezgif.com-webp-to-jpg.jpg)
[POSTER] Fecal microbiota profile at diagnosis in the French IMODI cohort of breast cancer
Oumaïra Rahmouni (1), Cindy Pensec (1), Steven Roblin (1), Yao Amouzou (1), Amandine Charreton (2), Patricia Lapierre...
![[Poster] A prospective observational study on breast cancer in Lyon and Dijon: description of the “breast cohort” of the IMODI project](https://www.biofortis.fr/wp-content/uploads/2019/07/imodi2-504x675.png)
[Poster] A prospective observational study on breast cancer in Lyon and Dijon: description of the “breast cohort” of the IMODI project
Oumaïra Rahmouni (1), Basile Frilley (1), Angélina Dion (1), Florence Gillaizeau (1), Amandine Charreton (2), Patricia...
Human Microbiome Therapeutics – Interview of Kristin Wanneberger (Ferring Pharmaceuticals)
Several kinds of Human Microbiome Therapeutics (HMTs) are emerging as excellent candidates for innovative health strategies, but some scientific and regulatory challenges remain. Despite no current market authorization, Fecal Microbiota Transplantation (FMT),...
Effects of pemetrexed chemotherapy on gut microbiota and digestive inflammation in Patient-Derived Tumor Xenograft (PDX) Models
C. PENSEC, T. CARTON, S. LEUILLET, D. GUENOT, IMODI Consortium, M. CAMPONE, H. BLOTTIERE, F. LE VACON Introduction Despite significant progress in anti-cancer treatment such as immunotherapy, chemotherapy remains a gold standard. Pemetrexed is a chemotherapeutic agent...
Microbiome and Performance. Interview from Jonathan Scheiman (FitBiomics)
Biofortis Mérieux NutriSciences met Jonathan Scheiman, co-founder and CEO of the company FitBiomics (Boston, USA) during the 2018 Probiota Event. In the field of sport and nutrition innovation, we found relevant to interview him about FitBiomics' history and...
The Microbiome Dysbiosis Ambiguity
As discussed previously, studying the microbiome has become of interest for many therapeutic applications. Thereby more and more projects include microbiome analysis. Talking about the microbiome often goes hand in hand with the word dysbiosis, especially when...
The human microbiome: The third microbiome wave is underway with the emergence of private microbiome platforms
The microbiome field is currently at the beginning of the third wave with ongoing development of therapeutic solutions, an increasing number of products in clinical phases, and the creation of several CROs/microbiome platforms providing various dedicated services such...
The human microbiome: an emerging microbiome biotech ecosystem, dominated by the United States
In this fifth chapter on the human microbiome, we investigate how life science investors biotech and big pharma have started to pour significant amounts of money in the field, with the hope to turn some of this research into innovative drugs. Cumulated fundings raised...